Houten, the Netherlands – March 24, 2021

Using its unique Confocal PET technology, MILabs B.V has succeeded in realizing another breakthrough in preclinical PET imaging. As published in Physics Word of March 2021, MILabs’ unique confocal PET technology magnifies all beneficial photons emitted from PET tracers to deliver images with a significant resolution improvement and can do so for multiple PET tracers simultaneously. This so-called Spectral PET, or Color PET, enables simultaneous detection of dual isotopes such as, e.g., 18F/89Zr and 124I/18F. Moreover, unwanted photons causing noise background that coincidently co-occur are rejected by Confocal PET, hence dramatically improving signal-to-noise contrast of the images.

press release MILabs 2021 march PET breakthrough
Confocal PET scanning enables to image different PET tracers at different colors,
hence complementing the detailed morphological info provided by Spectral CT

In addition, as illustrated, MILabs U-PET/CT now uses Spectral PET combined with Spectral CT, hence expanding applications way beyond the capabilities of any other preclinical PET/CT systems in terms of delivering contrast-enhanced, morphological, molecular PET/CT images.

According to Prof F. Beekman, CEO/CSO of MILabs, “The applications are game-changing. With a single PET/CT acquisition, one can follow multiple molecular interactions under the same physical and physiological conditions while visualizing animal morphology with Spectral CT. Moreover, besides studying and comparing two tracers, one can evaluate the complementary role of therapies under identical conditions, with images co-registered in space and time”. This ability dramatically facilitates translation from bench-to-clinic. “Because of the wide photon energy range of MILabs imaging approach, one can translate SPECT to PET and Targeted Anticancer Therapies (TAT) radionuclide therapy on a one-to-one basis. Add to this MILabs’ fully integrated Optical 3D tomography module, and with a single molecular imaging platform, one can genuinely cover applications from bench research to clinical trials.

About MILabs B.V.:
This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate innovative nuclear PET and SPECT techniques as well as Optical and CT imaging. MILabs has built a strong brand based on its mission of “Making Molecular Imaging Clear”. With ultra-high-resolution and multiparametric imaging complemented by theranostic capabilities, it provides efficient translational systems for both diagnostic and therapy applications. For more information, visit: www.milabs.com or contact MILabs at [email protected]

For further reading:
1. Physics World 5 March 2021, Tami Freeman-Editor, Nuclear Medicine Research Update
2. Physics in Medicine & Biology 2021, F J Beekman et al., Phys. Med. Biol. 66 065011


Share on social media

Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands – Prof. Harrie Weinans & Dr. Bart van der Wal

  – Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands –  – Prof. …

Read More →

Press Release: MILABS launches its 7th generation of preclinical imagers at the World Molecular Imaging Conference 2021

Under the new ownership of the Rigaku Group (Tokyo, Japan), MILabs is pushing the value …

Read More →

Press Release: RIGAKU Acquires Life Science Imaging Equipment Manufacturer MILabs

August 3, 2021 – Houten, the Netherlands Dear readers, We are very excited that MILabs …

Read More →

Press Release: Confocal PET Causes Spectral PET Breakthrough in Preclinical Imaging

Houten, the Netherlands – March 24, 2021 Using its unique Confocal PET technology, MILabs B.V …

Read More →

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University – Bridging the “valley of death” …

Read More →

Spotlight on Bart Cornelissen, PhD – Department of Oncology, Oxford Institute for Radiation Oncology at University of Oxford

– Targeting Tumors from the inside –   Dr. Bart Cornelissen is Group Leader and …

Read More →

Spotlight on Prof. Twan Lammers – ExMI-RWTH Aachen

A Pioneering Mind in Nanomedicine and Theranostics Prof. Dr. Dr. Twan Lammers is Head of …

Read More →

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the 2020 MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by Acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →
Scroll to Top